FindTrial
Sign In

EFFICACY OF ROSE HIP IN TREATMENT OF PAIN IN PATIENTS WITH COXARTHROSIS - ROSA_10

EFFICACY OF ROSE HIP IN TREATMENT OF PAIN IN PATIENTS WITH COXARTHROSIS - ROSA_10

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2010-018975-13-IT
Enrollment
Unknown
Registered
2012-04-12
Start date
2010-02-24
Completion date
Unknown
Last updated
2014-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PATIENTS TO BE IMPLANTED WITH HIP PROSTHESIS MedDRA version: 14.1 Level: SOC Classification code 10028395 Term: Musculoskeletal and connective tissue disorders System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders

Interventions

Trade Name: ALGIX Pharmaceutical Form: Coated tablet INN or Proposed INN: Etoricoxib Concentration unit: mg milligram(s) Concentration number: 60- Product Name: Rose Hip Product Code: NA Pharmaceutic

Sponsors

ISTITUTO ORTOPEDICO RIZZOLI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: PATIENTS TO BE IMPLANTED WITH HIP PROSTHESIS Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: AUTO-IMMUNE DISEASES

Design outcomes

Primary

MeasureTime frame
Main Objective: EVALUATION OF THE ANTI-DOLORIFC ACTIVITY OF ROSA CANINA ESTRACT;Secondary Objective: QUALITY OF LIFE PATIENTS;Primary end point(s): EVALUATION OF THE ANTI-DOLORIFC ACTIVITY OF ROSA CANINA ESTRACT—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026